Daniel Sherbenou
University of Colorado, Denver
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Daniel Sherbenou as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:25 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04925193 · Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple MyelomaUniversity of Colorado, Denver · active not recruiting · Multiple Myeloma in Relapse · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:25 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Targeting Cancer Initiating Cells in Multiple MyelomaK08CA222704 · NCI · UNIVERSITY OF COLORADO DENVER · fiscal years 2018 to 2022 · $221,856 awarded in 2022Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Research Training and Education CoordinationP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · fiscal years 2009 to 2026Named on NCT04925193
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:25 UTC. The ranking covers the 200 most relevant of 3 PubMed records, and a shared surname and initials can bring in a namesake. All 3 on PubMed
- Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.Lancet Haematol · 2019219 citationsRCR 7.2
- A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.Biol Blood Marrow Transplant · 20178 citationsRCR 0.3
- Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma.Am J Hematol · 20196 citationsRCR 0.3